World Health Organization. (2022). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. IARC Press.
[2]
Arber, D.A., et al. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Blood, 140(11), 1200-1228.
[3]
Cazzola, M. (2020). Myelodysplastic Syndromes. New England Journal of Medicine, 383(14), 1358-1374.
[4]
Malcovati, L., et al. (2021). SF3B1-mutant myelodysplastic syndromes: pathophysiology and clinical outcomes. Blood, 138(21), 2021-2033.
[5]
Platzbecker, U., et al. (2022). Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (MEDALIST): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 23(4), 519-530.